Skip to main content

Featured article: Global conserved RBD fraction of SARS-CoV-2 S-protein with T500S mutation in silico significantly blocks ACE2 and rejects viral spike

SARS-CoV-2 developed a global-pandemic with millions of infections/deaths. As it is urgently necessary, it is assumed that some blockers/inhibitors of ACE2 could be helpful to resist the binding of viral-spike Receptor-Binding-Domain (RBD).

In this research article, Banerjee and colleagues investigate a suitable and universal blocker by competing with the spike protein of the SARS CoV-2 virus. Findings demonstrate that CUT4-mutant rejects whole glycosylated-nCoV2 in all pre-dock, post-dock and competitive-docking conditions. Results have a great therapeutic implication to develop an efficient and universal blocker for SARS CoV-2. 


Why publish with us

  • Home for all valid research within pre-clinical and translational medicine
  • Gold open access and compatible with growing funder mandates
  • Expert Section Editors and an international Editorial Board 
  • Free access to all content, ensuring a wide dissemination of articles
  • High article accesses with more than 117,574 full-article downloads in 2021
  • Companion journal to Journal of Translational Medicine

Aims and scope

Translational Medicine Communications is an interdisciplinary forum for all scientifically valid research from across translational medicine. We publish research that focuses on the biology of disease, as well as preclinical and basic research that is closely associated with medicine. Translational Medicine Communications will also consider reviews, methodology articles, protocols and commentaries.
Our aim is to improve transparency and reproducibility within translational medicine, which is why we consider research papers regardless of outcome or significance of findings, as well as protocols for future research. We aim to serve the translational science community by publishing all scientifically valid and technically sound articles and we are dedicated to facilitating the communication between basic and clinical science.

Translational Medicine Communications is the companion journal to Journal of Translational Medicine.

Journal of Translational Medicine considers articles focusing on information derived from human experimentation to optimise the communication between basic and clinical science.

Explore the companion journal

Editor-in-Chief: Francesco Marincola, Kite Pharma, USA

Dr. Marincola is Global Head of Research at Kite Pharma, Santa Monica, California. He was previously President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation; Chief Research Officer at Sidra Research, Qatar; and Tenured Investigator at the National Institutes of Health, Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine and is the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and the International Society for Translational Medicine. He edited several books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is also an award winning fiction author of The Wise Men of Pizzo and Cat Behind the Window.

Annual Journal Metrics

  • Speed
    37 days to first decision for all manuscripts (Median)
    36 days to first decision for reviewed manuscripts only (Median)

    116,990 Downloads (2021)
    168 Altmetric mentions (2021)